CN102149682B - 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途 - Google Patents

1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途 Download PDF

Info

Publication number
CN102149682B
CN102149682B CN2010800025583A CN201080002558A CN102149682B CN 102149682 B CN102149682 B CN 102149682B CN 2010800025583 A CN2010800025583 A CN 2010800025583A CN 201080002558 A CN201080002558 A CN 201080002558A CN 102149682 B CN102149682 B CN 102149682B
Authority
CN
China
Prior art keywords
amino
trifluoromethylpyridin
phenyl
chloro
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2010800025583A
Other languages
English (en)
Chinese (zh)
Other versions
CN102149682A (zh
Inventor
胡高云
陶立坚
陈军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Central South University
Original Assignee
Central South University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Central South University filed Critical Central South University
Priority to CN2010800025583A priority Critical patent/CN102149682B/zh
Publication of CN102149682A publication Critical patent/CN102149682A/zh
Application granted granted Critical
Publication of CN102149682B publication Critical patent/CN102149682B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2010800025583A 2009-05-25 2010-05-24 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途 Active CN102149682B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010800025583A CN102149682B (zh) 2009-05-25 2010-05-24 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200910043501 2009-05-25
CN200910043501.7 2009-05-25
PCT/CN2010/073105 WO2010135972A1 (zh) 2009-05-25 2010-05-24 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途
CN2010800025583A CN102149682B (zh) 2009-05-25 2010-05-24 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途

Publications (2)

Publication Number Publication Date
CN102149682A CN102149682A (zh) 2011-08-10
CN102149682B true CN102149682B (zh) 2012-12-05

Family

ID=43222160

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800025583A Active CN102149682B (zh) 2009-05-25 2010-05-24 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途

Country Status (7)

Country Link
US (1) US8426407B2 (https=)
EP (1) EP2436670B1 (https=)
JP (1) JP5583758B2 (https=)
KR (1) KR101522924B1 (https=)
CN (1) CN102149682B (https=)
AU (1) AU2010252447B2 (https=)
WO (1) WO2010135972A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5587184B2 (ja) 2007-06-20 2014-09-10 オースペックス・ファーマシューティカルズ・インコーポレイテッド 繊維症阻害剤としての置換n−アリールピリジノン
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
CN102786467A (zh) * 2012-08-15 2012-11-21 浙江省医学科学院 一种n-取代芳基吡啶酮化合物及其制备方法和应用
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
ES2663806T3 (es) 2013-12-19 2018-04-17 unshine Lake Pharma Co., Ltd. Derivados heterocíclicos nitrogenados y su aplicación en el tratamiento de la fibrosis tisular
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
WO2015171345A1 (en) * 2014-04-30 2015-11-12 Auspex Pharmaceuticals, Inc. N-aryl pyridinones modulators of fibrosis and/or collagen infiltration
CN106466318B (zh) * 2015-08-21 2019-01-01 中南大学 1-杂环取代苄基吡啶酮类化合物在制备治疗糖尿病肾病药物中的应用
CN113476447A (zh) * 2021-07-09 2021-10-08 中南大学 一种美氟尼酮在制备急性肝损伤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1386737A (zh) * 2002-06-11 2002-12-25 中南大学湘雅医学院 抗纤维化吡啶酮药物及其生产工艺方法
CN101237869A (zh) * 2005-05-10 2008-08-06 英特芒尼公司 用于调节应激-活化蛋白激酶系统的吡啶酮衍生物
CN101235030A (zh) * 2007-01-30 2008-08-06 中南大学 1-取代-5-三氟甲基-2-(1h)吡啶酮化合物、制备方法及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
GB8523126D0 (en) 1985-09-19 1985-10-23 Ici Plc Aryl pyridones
GB8621217D0 (en) 1986-09-03 1986-10-08 Ici Plc Chemical compounds
GB8825314D0 (en) 1988-10-28 1988-11-30 Ici Plc Chemical compounds
GB9006479D0 (en) 1989-04-17 1990-05-23 Ici Plc Novel compounds
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5238906A (en) 1990-11-27 1993-08-24 Sumitomo Chemical Company, Limited Pyridone derivatives and use
DE4343528A1 (de) 1993-12-16 1995-06-22 Schering Ag Zweifach heterocyclisch substituierte Benzole und Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
RS52392B (sr) 2002-02-14 2013-02-28 Pharmacia Corporation Supstituisani piridinoni kao modulatori p38 map kinaze
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
JP4614884B2 (ja) * 2003-11-14 2011-01-19 シャンハイ ゲノミックス インク ピリドンの誘導体とその使用
DE102004027359A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
JP2009517390A (ja) 2005-11-23 2009-04-30 インターミューン インコーポレイテッド ストレス活性化プロテインキナーゼ系を調節する方法
US20090118135A1 (en) 2007-06-08 2009-05-07 The Burnham Institute Methods and compounds for regulating apoptosis
CN101371833A (zh) 2007-08-23 2009-02-25 中南大学 1-芳基-2(1h)-吡啶酮类化合物在制备治疗皮肤瘙痒药物中的应用
CA2726588C (en) * 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
AU2010206543A1 (en) 2009-01-26 2011-07-07 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders
WO2010135470A1 (en) 2009-05-19 2010-11-25 Intermune, Inc. Pifenidone derivatives for treating bronchial asthma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1386737A (zh) * 2002-06-11 2002-12-25 中南大学湘雅医学院 抗纤维化吡啶酮药物及其生产工艺方法
CN101237869A (zh) * 2005-05-10 2008-08-06 英特芒尼公司 用于调节应激-活化蛋白激酶系统的吡啶酮衍生物
CN101235030A (zh) * 2007-01-30 2008-08-06 中南大学 1-取代-5-三氟甲基-2-(1h)吡啶酮化合物、制备方法及其用途

Also Published As

Publication number Publication date
KR101522924B1 (ko) 2015-05-26
JP5583758B2 (ja) 2014-09-03
JP2012527487A (ja) 2012-11-08
EP2436670B1 (en) 2014-04-16
WO2010135972A1 (zh) 2010-12-02
US8426407B2 (en) 2013-04-23
CN102149682A (zh) 2011-08-10
AU2010252447B2 (en) 2014-08-28
US20120142688A1 (en) 2012-06-07
KR20120025541A (ko) 2012-03-15
AU2010252447A1 (en) 2011-12-15
EP2436670A1 (en) 2012-04-04
HK1164297A1 (en) 2012-10-12
EP2436670A4 (en) 2012-11-21

Similar Documents

Publication Publication Date Title
CN102149682B (zh) 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途
CN102149683B (zh) 1-(取代苄基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐,其制备方法及其用途
CN105237527B (zh) 苯并咪唑衍生物及其制备方法和医药用途
EP1783116B1 (en) 2-phenylpyridine derivative
JP6667507B2 (ja) ピラゾロ[3,4−c]ピリジン誘導体
CN102807575B (zh) 3-芳基-5-噻吩基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用
WO2016145622A1 (zh) 苯并咪唑衍生物及其制备方法和医药用途
BRPI1003506A2 (pt) composto, composiÇço farmacÊutica, uso de um composto e mÉtodo de tratamento dps distérbios associados aos receptores serotoninÉrgicos 5-ht1a e 5-ht2a
CN105153141B (zh) 苯并咪唑衍生物及其制备方法和医药用途
CN101012201A (zh) 川芎嗪衍生物、其制备方法及其医药用途
CN102250099B (zh) 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
CN101010300A (zh) 2-苯基吡啶衍生物
HK1164297B (en) Preparation of 1-(substituted aryl)-5-trifluoromethyl-2-(1h)-pyridone compounds and salts thereof and their applications
HK1166791B (en) Preparation of 1-(substituted benzyl)-5-trifluoromethyl-2-(1h)pyridone compounds and salts thereof and their applications
CN101463032A (zh) 用作正性肌力药物的4,5-二氢-[1,2,4]-三氮唑并[4,3-a]喹啉衍生物
CN114315705A (zh) 一类urat1抑制剂及其制备方法与用途
WO2016019849A1 (zh) 一种达比加群烷酯衍生物及其制备方法和在药学上的用途
CN102336740B (zh) 一类咪唑类化合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant